Sometimes, it is hard to prove what you know to be true is actually true. So, it’s nice to know there is a paper confirming something I have also known to be true: People who lose visual acuity as a result of cataracts will-if they have cataract surgery to restore their vision-live longer than those who do not have surgery.
Alcon Laboratories has announced the global launch of its phacoemulsification technology platform, a vision system designed to provide surgeons with enhanced cataract removal capabilities.
Clarity Medical Systems Inc.’s compact wavefront sensor module has received a patent from the U.S. Patent and Trademark Office.
ThromboGenics NV has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize drugs inhibiting a specific target for the treatment of diabetic macular edema (DME).
The use of modern surgical techniques with or without IOL implantation does not eliminate the development of glaucoma or suspected glaucoma, according to recent study results.
Rigel Pharmaceuticals Inc. has announced its plans to focus the company’s resources on the completion of three lead clinical programs, including dry eye.
Identifying hypopituitarism in children with optic nerve hypoplasia (ONH) is important because they are at risk of impaired growth, hypoglycemia, seizures, brain damage, and death, according to Paul H. Phillips, MD.
Clarity Medical Systems Inc. has received a patent on optimizing vision correction procedures from the U.S. Patent and Trademark Office.
Prevent Blindness America (PBA) has dedicated the month of September as Sports Eye Safety Awareness Month in order to educate the public on the best ways to keep eyes safe while partaking in sports activities.
Bernard Becker, MD, chairman of the ophthalmology department at the Washington University School of Medicine in St. Louis for 35 years, has died.
Regeneron Pharmaceuticals’ new treatment for visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) has been approved by the European Commission.
A prospective study randomly assigned 64 patients with open-angle glaucoma to surgery with a miniature glaucoma shunt or standard trabeculectomy, both with mitomycin-C.
Latanoprostene bunod is a probable new drug for the treatment of glaucoma that seems to be well tolerated and potent in lowering IOP.
A new fixed-combination of brinzolamide-brimonidine is a safe and effective option for lowering IOP in patients who are not candidates for a beta-blocker.
There are several vital components surgeons need to take into consideration when treating children who have traumatic cataracts.
An investigational non-invasive imaging tool, phase-sensitive optical coherence tomography can be used to detect and measure movement of the trabecular meshwork in vivo.
In an analysis of almost 2,000 eyes treated with selective laser trabeculoplasty as primary therapy for glaucoma, mean IOP decreased 29% and the cumulative probability of success at 10 years was 90%.
Research shows circadian variations in IOP can be regulated by orexin-containing neurons located in the hypothalamus
In a comparison of two wavefront-guided excimer lasers, one platform provides better clinical results on some measures but cannot image certain eyes. The other system can image nearly all eyes, but has slightly less robust clinical results.
Visual loss and progressive thinning of the retinal nerve fiber layer (RNFL) occur over time in patients with multiple sclerosis (MS), according to results from a longitudinal study.
What can we ophthalmologists in the wealthiest country in the Western Hemisphere learn from the success stories of ophthalmic institutions in other countries with different cultures, histories, and degrees of wealth? A great deal, notes Peter J. McDonnell, MD.
Even though the end result may not be the most ideal for you, there are still people out there who will sacrifice if the conclusion benefits the majority.
Patient selection plays just as much of a role in the success of endoscopic cyclophotocoagulation as do surgical pearls. Identifying the proper patient population is a key for greater success.
As society continues to become more technologically advanced and patient expectations grow alongside, there is no better time for physicians to rework the antiquated eyedrop-centered glaucoma treatment regime. SLT offers the treatment efficacy and convenience patients today need and stands to give the 1970s-based management of glaucoma a long-awaited shake-up in the 2010s.
Early problems associated with femtosecond laser-assisted refractive cataract surgery have been successfully downsized thanks to ongoing platform improvements and the introduction of new surgical instruments and techniques.
A new eye vitamin and mineral supplement was introduced by Bausch + Lomb at the 2013 American Society of Retina Specialists annual meeting.
The CDSCO has granted regulatory approval to STAAR Surgical’s implantable lens technology in India.
San Francisco-The Glaucoma Research Foundation (GRF) has received a $3 million bequest, the largest gift in its history.
Treatment of thyroid eye disease varies greatly among physicians.
.png "Optometry Times"){kind=logo}
